Pebarin Special Precautions

There have been reports in the postmarketing experience of angioedema, such as swelling of the face, mouth and neck, including cases of hypersensitivity reactions. If symptoms occur, Pregabalin should be discontinued immediately. Use with caution in patients with a history of angioedema and concurrent use with other drugs known to cause angioedema e.g. angiotensin-converting enzyme inhibitors (ACEI).
Antiepileptic drugs (AED), including Pregabalin, should not be abruptly discontinued because of the possibility of increasing seizure frequency. Therefore, if Pregabalin is discontinued, dosage should be tapered gradually over at least 1 week.
Antiepileptic drugs (AED), including Pregabalin, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Monitor patients treated with any AED for any indication for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.
Pregabalin may cause peripheral edema. Concomitant use of Pregabalin with a thiazolidinedione antidiabetic agent has been associated with a greater risk of developing weight gain and peripheral edema than either drug alone. Therefore use caution when coadministering Pregabalin and these agents.
Because there are limited data regarding use of Pregabalin in patients with New York Heart Association (NYHA) class III or IV congestive heart failure, the drug should be used with caution in these patients.
Pregabalin may cause weight gain. Pregabalin-associated weight gain was related to dose and duration of exposure. However, weight gain did not appear to be associated with baseline body mass index (BMI), gender, or age.
Pregabalin may cause visual disturbance e.g. blurred vision, decreased visual acuity and visual field changes. Patients should be instructed to notify their physician if these effects are noted.
Pregabalin has been associated with increases in creatine kinase. Rhabdomyolysis has been reported in premarketing clinical trials. However, the relationship between this event and Pregabalin is not completely understood. Therefore, patients should be instructed to notify their physician if unexplained muscle pain, tenderness, or weakness, particularly if fever and/or malaise are associated with these symptoms.
Pregabalin is associated with a decrease in platelet count and prolonged PR interval.